If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Run-flat tires === The introduction of run-flat tires and emergency spare tires by several tire and vehicle manufacturers has provided motivation to make at least some basic TPMS mandatory when using run-flat tires. With run-flat tires, the driver will most likely not notice that a tire is running flat, hence the so-called "run-flat warning systems" were introduced. These are most often first generation, purely roll-radius based iTPMS, which ensure that run-flat tires are not used beyond their limitations, usually 80 km/h (50 mph) and 80 km (50 miles) driving distance. The iTPMS market has progressed as well. Indirect TPMS are able to detect under-inflation through combined use of roll radius and spectrum analysis and hence four-wheel monitoring has become feasible. With this breakthrough, meeting the legal requirements is possible also with iTPMS.
=== In the laboratory === Many aspects of bird biology are difficult to study in the field. These include the study of behavioural and physiological changes that require a long duration of access to the bird. Nondestructive samples of blood or feathers taken during field studies may be studied in the laboratory. For instance, the variation in the ratios of stable hydrogen isotopes across latitudes makes establishing the origins of migrant birds possible using mass spectrometric analysis of feather samples. These techniques can be used in combination with other techniques such as ringing. The first attenuated vaccine developed by Louis Pasteur, for fowl cholera, was tested on poultry in 1878. Anti-malarials were tested on birds which harbour avian-malarias. Poultry continues to be used as a model for many studies in non-mammalian immunology.
=== Unofficial === Insulin resistance in the brain caused by Alzheimer's disease has been termed by some researchers as Type 3 diabetes, though this label is also rejected by some to avoid confusion with other types classified as Type 3. "Type 4 diabetes" has been used to describe age-related insulin resistance in lean mice. Neither of these terms are commonly used in human health care.
=== Regulation === In vertebrates, the secretion of melatonin is regulated through the activation of the beta-1 adrenergic receptor by the hormone norepinephrine. Norepinephrine increases the concentration of intracellular cAMP via beta-adrenergic receptors, which in turn activates the cAMP-dependent protein kinase A (PKA). PKA then phosphorylates arylalkylamine N-acetyltransferase (AANAT), the penultimate enzyme in the melatonin synthesis pathway. When exposed to daylight, noradrenergic stimulation ceases, so AANAT is not phosphorylated. In the absence of phosphorylation, AANAT is immediately degraded by proteasomal proteolysis. Blue light, especially within the 460–480 nm range, inhibits the biosynthesis of melatonin, with the degree of suppression being directly proportional to the intensity and duration of light exposure. Historically, humans in temperate climates experienced limited exposure to blue daylight during winter months, primarily receiving light from sources that emitted predominantly yellow light, such as fires. The incandescent light bulbs used extensively throughout the 20th century emitted relatively low levels of blue light. It has been found that light containing only wavelengths greater than 530 nm does not suppress melatonin under bright-light conditions. The use of glasses that block blue light in the hours preceding bedtime can mitigate melatonin suppression.
=== Other uses === Bupropion is not effective in the treatment of cocaine dependence, but it is showing promise in reducing drug use in treating amphetamine-type stimulant use and cravings. Based on studies indicating that bupropion lowers the level of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α), there have been suggestions that it might be useful in treating inflammatory bowel disease, psoriasis, and other autoimmune conditions, but very little clinical evidence is available. Bupropion is not proven to be effective in treating chronic low back pain. The drug may be useful in the treatment of excessive daytime sleepiness (EDS) and narcolepsy. Bupropion has been used to treat disorders of diminished motivation, like apathy, abulia, and akinetic mutism. Accordingly, the drug has been found to increase effort expenditure and improve motivational deficits in animal models. However, only limited benefits of bupropion in the treatment of apathy have been observed in clinical trials in various conditions. Bupropion has been used in the treatment of orthostatic hypotension and postural orthostatic tachycardia syndrome (POTS).
Sources: en.wikipedia.org
Most chloroplasts in a photosynthetic cell do not develop directly from proplastids or etioplasts. In fact, a typical shoot meristematic plant cell contains only 7–20 proplastids. These proplastids differentiate into chloroplasts, which divide to create the 30–70 chloroplasts found in a mature photosynthetic plant cell. If the cell divides, chloroplast division provides the additional chloroplasts to partition between the two daughter cells. In single-celled algae, chloroplast division is the only way new chloroplasts are formed. There is no proplastid differentiation—when an algal cell divides, its chloroplast divides along with it, and each daughter cell receives a mature chloroplast. Almost all chloroplasts in a cell divide, rather than a small group of rapidly dividing chloroplasts. Chloroplasts have no definite S-phase—their DNA replication is not synchronized or limited to that of their host cells. Much of what we know about chloroplast division comes from studying organisms like Arabidopsis and the red alga Cyanidioschyzon merolæ.
The protest demonstration soon erupted into a riot; the crowd took to the streets, placing the capital, like Timișoara, in turmoil. Members of the crowd spontaneously began shouting anti-Ceaușescu slogans, which spread and became chants: "Jos dictatorul!" ("Down with the dictator"), "Moarte criminalului!" ("Death to the criminal"), "Noi suntem poporul, jos cu dictatorul!" ("We are the people, down with the dictator"), "Ceaușescu cine ești?/Criminal din Scornicești" ("Ceaușescu, who are you? A criminal from Scornicești").
In humans, glucose is metabolized by glycolysis and the pentose phosphate pathway. Glycolysis is used by all living organisms, with small variations, and all organisms generate energy from the breakdown of monosaccharides. In the further course of the metabolism, it can be completely degraded via oxidative decarboxylation, the citric acid cycle (synonym Krebs cycle) and the respiratory chain to water and carbon dioxide. If there is not enough oxygen available for this, the glucose degradation in animals occurs anaerobic to lactate via lactic acid fermentation and releases much less energy. Muscular lactate enters the liver through the bloodstream in mammals, where gluconeogenesis occurs (Cori cycle). With a high supply of glucose, the metabolite acetyl-CoA from the Krebs cycle can also be used for fatty acid synthesis. Glucose is also used to replenish the body's glycogen stores, which are mainly found in liver and skeletal muscle. These processes are hormonally regulated. In other living organisms, other forms of fermentation can occur. The bacterium Escherichia coli can grow on nutrient media containing glucose as the sole carbon source. In some bacteria and, in modified form, also in archaea, glucose is degraded via the Entner-Doudoroff pathway. With glucose, a mechanism for gene regulation was discovered in E. coli, the catabolite repression (formerly known as glucose effect). Use of glucose as an energy source in cells is by either aerobic respiration, anaerobic respiration, or fermentation.
==== United States ==== Etizolam is not authorized by the FDA for medical use in the US. As of March 2016, etizolam is a controlled substance in the following states: Alabama, Arkansas, Florida, Georgia (as Schedule I), Louisiana, Mississippi, Texas, South Carolina, and Virginia. It is controlled in Indiana as of 1 July 2017. It is controlled in Ohio as of February 2018. On 23 December 2022, the DEA announced it had begun consideration on the matter of placing etizolam under temporary Schedule I status. Later on 25 July 2023, the DEA published a pre-print notice that etizolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025. On 25 July 2025, and effective the following day, the DEA extended the temporary scheduling until 26 July 2026. Effective 1 April 2026, etizolam is permanently in Schedule I under the Controlled Substances Act.
=== 16 September === The RSF carried out a drone attack that destroyed an ammunition dump within the garrison of the SAF's Fifth Division in El Obeid, resulting in an unspecified number of casualties.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.